TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20713181

Group type: EXPERIMENTAL
Intervention: Minnesota Method 1 - Mail only
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Minnesota Method 2 - Mail and selective phone calls
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: New Mexico Method 3 - Mail and non-selective phone calls
Number of subjects: 623
Study: 18950181

Group type: EXPERIMENTAL
Intervention: Raw broccoli
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cooked broccoli
Number of subjects: 8
Study: 16000178

Group type: EXPERIMENTAL
Intervention: Electronic voting system
Number of subjects: 102
Study: 11897269

Group type: EXPERIMENTAL
Intervention: CHO[4:1] meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BAL[1:1] meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PRO[1:4] meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BAL[1:1] and PRO[1:4] meals
Number of subjects: 15
Study: 9890391

Group type: EXPERIMENTAL
Intervention: E5510 (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: E5510
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9
Study: 8808232

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg daily for 4 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 25
Study: 1773690

Group type: EXPERIMENTAL
Intervention: Topical phenytoin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dry sterile occlusive dressing (Control)
Number of subjects: 50
Study: 7171880

Group type: EXPERIMENTAL
Intervention: Information about the surgical procedure and its effects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive coping technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General information about the ward
Number of subjects: 60

Group type: COMPARATOR
Intervention: Declined psychological help
Number of subjects: 60
Study: 30284597

Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468 with diltiazem (240 mg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468 after a high-fat high-calorie breakfast
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468 alone or in combination with diltiazem, midazolam, or food
Number of subjects: 34
Study: 29054803

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Kinesiotaping (KT)
Number of subjects: 35
Study: 26296296

Group type: EXPERIMENTAL
Intervention: IPL exposure of 0, 7, 8, or 10 J/cm2
Number of subjects: 16

Group type: COMPARATOR
Intervention: UVR exposure (three standard erythema doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of IPL and UVR
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pain measurement
Number of subjects: 16

Group type: COMPARATOR
Intervention: UVR exposure after IPL
Number of subjects: 16
Study: 24075623

Group type: EXPERIMENTAL
Intervention: Family-based weight management program (2-year intervention)
Number of subjects: 1093
Study: 21134472

Group type: EXPERIMENTAL
Intervention: Standard antidepressant medication (tricyclic, typical serotonin‐norepinephrine reuptake inhibitor, or typical selective serotonin reuptake inhibitor)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: SVM applied to gray matter
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: SVM applied to white matter
Number of subjects: 61
Study: 19244458

Group type: EXPERIMENTAL
Intervention: Abbott Determine SR test
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Trinity Biotech Capillus SR test
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Parallel SR tests
Number of subjects: 789

Group type: COMPARATOR
Intervention: Parallel ELISA tests
Number of subjects: 789
Study: 17968021

Group type: EXPERIMENTAL
Intervention: VCAP-AMP-VECP
Number of subjects: 118

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 118
Study: 15378145

Group type: EXPERIMENTAL
Intervention: Colchicine administered in 2 or 3 divided doses daily (Group I)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Colchicine administered as a single daily dose (Group II)
Number of subjects: 39
Study: 11469730

Group type: EXPERIMENTAL
Intervention: General Function Score (GFS)
Number of subjects: 297
Study: 9743895

Group type: EXPERIMENTAL
Intervention: Org 31710 (75 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Org 31710 (10, 25, 50, or 75 mg)
Number of subjects: 24
Study: 7942055

Group type: EXPERIMENTAL
Intervention: Electrically induced cycling with complete epidural anaesthesia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Voluntary exercise
Number of subjects: 8
Study: 3169216

Group type: EXPERIMENTAL
Intervention: Terbutaline (2.0 mg cumulative dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline (4 mg cumulative dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 0
Study: 30971134

Group type: EXPERIMENTAL
Intervention: Lecture-based education (Group 2)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Peer-leader education (Group 3)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 408
Study: 28831957

Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15% energy, average 43 g/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (abstaining from walnut consumption)
Number of subjects: 100
Study: 25925591

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg) intravenously prior to loading dose of ticagrelor (180 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo prior to loading dose of ticagrelor (180 mg)
Number of subjects: 100
Study: 23108496

Group type: EXPERIMENTAL
Intervention: Atropine (10 μg/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 56
Study: 22133036

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) therapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) without corticosteroids
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) with corticosteroids
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methotrexate polyglutamate concentrations
Number of subjects: 17
Study: 19637519

Group type: EXPERIMENTAL
Intervention: Admira Protect
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VivaSens
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hyposen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study: 16982274

Group type: EXPERIMENTAL
Intervention: Resilon points, Epiphany Primer, and Root Canal Sealant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gutta‐percha and Kerr Pulp Canal Sealer EWT
Number of subjects: 30
Study: 15600229

Group type: EXPERIMENTAL
Intervention: Aware group (AG)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Unaware group (UG)
Number of subjects: 68
Study: 11251748

Group type: EXPERIMENTAL
Intervention: Discussions of advance directives
Number of subjects: 686
Study: 9210853

Group type: EXPERIMENTAL
Intervention: Repeated presentation of word pairs as prime-target pairs in a lexical decision task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral pairs
Number of subjects: 0
Study: 8236142

Group type: EXPERIMENTAL
Intervention: Sarulplase 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sarulplase 40 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sarulplase (both doses)
Number of subjects: 6
Study: 3652656

Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanic acid (Timentin)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 224
Study: 31360536

Group type: EXPERIMENTAL
Intervention: Tablet computer technology's audio-visual facility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provision of baseline PRO responses prior to follow-up questionnaires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice of completing a questionnaire independently of previous responses
Number of subjects: 0
Study: 27843051

Group type: EXPERIMENTAL
Intervention: Drospirenone/Estradiol (DRSP/E2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tibolone (T)
Number of subjects: 24
Study: 27074034

Group type: EXPERIMENTAL
Intervention: Combined H1R and H2R antagonist (fexofenadine and ranitidine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 49
Study: 24933238

Group type: EXPERIMENTAL
Intervention: Denervation group (surgical denervation by excision of 1 cm of proximal thoracodorsal nerve)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Innervation group (thoracodorsal nerve saved intact)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (denervated and innervated)
Number of subjects: 28
Study: 22646304

Group type: EXPERIMENTAL
Intervention: Stillbirths (105 total, 65 fresh)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Neonatal deaths (116 total, 87 early)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Delays in care (201 individual delays in 121/187 birth narratives)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Delays in seeking care
Number of subjects: 221
Study: 19783589

Group type: COMPARATOR
Intervention: Strontium ranelate (SR)
Number of subjects: 0
Study: 17583098

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass allergen tablets (standardized tablet at different doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass allergen tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 15309971

Group type: EXPERIMENTAL
Intervention: PTX 1200 mg orally/day for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 6 months followed by PTX for another 6 months
Number of subjects: 18
Study: 12645166

Group type: EXPERIMENTAL
Intervention: Group-I regimen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group-II regimen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group-III regimen
Number of subjects: 90
Study: 10734372

Group type: EXPERIMENTAL
Intervention: Androhep®
Number of subjects: 1431

Group type: COMPARATOR
Intervention: X-CELL(TM)
Number of subjects: 1431
Study: 7753895

Group type: EXPERIMENTAL
Intervention: Coffee A (USA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coffee B (treated from Europe)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coffee C (untreated from Europe)
Number of subjects: 20
Study: 2487552

Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective beta-blocker)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Oxazepam (benzodiazepine)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 656294

Group type: EXPERIMENTAL
Intervention: delta1-tetrahydrocannabinol (delta1-THC) administered in 62 microliter metered volumes containing 50-200 microgram by inhalation from an aerosol device
Number of subjects: 1
Study: 31968988

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-acupuncture (SA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-acupuncture (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study: 31046016

Group type: EXPERIMENTAL
Intervention: Combination treatment of 0.01% atropine and +2.50‐diopter add center‐distance soft bifocal contact lenses (SBCL) for 2 weeks
Number of subjects: 49
Study: 28536730

Group type: EXPERIMENTAL
Intervention: Climate heliotherapy (CHT) for 3 weeks
Number of subjects: 163
Study: 25962165

Group type: EXPERIMENTAL
Intervention: BG00010 (neublastin, artemin, enovin) 0.3, 1, 3, 10, 25, 50, 100, 200, 400, or 800 μg/kg (intravenous) or 50 μg/kg (subcutaneous)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BG00010
Number of subjects: 48
Study: 25489146

Group type: EXPERIMENTAL
Intervention: S-POP classification system
Number of subjects: 100

Group type: COMPARATOR
Intervention: POPQ classification system
Number of subjects: 100
Study: 22370319

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin/gemcitabine (PCG)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 626
Study: 19029093

Group type: EXPERIMENTAL
Intervention: Priming dose followed by bolus (0.06+0.94 mg kg(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.5 mg kg(‐1) bolus
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1.0 mg kg(‐1) bolus
Number of subjects: 90
Study: 17308317

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Amlodipine (10 mg daily)
Number of subjects: 27
Study: 15033251

Group type: EXPERIMENTAL
Intervention: ITF-1697 (0.1 microg/kg/min)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: ITF-1697 (1.0 microg/kg/min)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: ITF-1697 (0.5 microg/kg/min)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: ITF-1697 (2.0 microg/kg/min)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: All ITF-1697 dosages
Number of subjects: 402
Study: 11695068

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg and calcium 1000 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Calcitonin 100 IU and calcium 1000 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Calcium 1000 mg
Number of subjects: 151
Study: 9892908

Group type: COMPARATOR
Intervention: Calcipotriol/vehicle
Number of subjects: 699

Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Calcipotriol/clobetasone 17‐butyrate
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone 17‐valerate
Number of subjects: 699
Study: 8069886

Group type: EXPERIMENTAL
Intervention: NaF dentifrice brushed three times daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing device (FRD; 0.07 mg F/day) plus F‐free dentifrice
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FRD (0.232 mg F/day) plus F‐free dentifrice
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FRD (0.232 mg F/day) plus NaF dentifrice
Number of subjects: 28

Group type: COMPARATOR
Intervention: F‐free dentifrice three times daily
Number of subjects: 28
Study: 2495079

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin 75 mg combined with Warfarin
Number of subjects: 20
Study: 794726

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 370
Study: 31153882

Group type: EXPERIMENTAL
Intervention: Early TIPS (within 72 hours after initial endoscopy)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Early TIPS
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (standard treatment with vasoactive drugs and endoscopic band ligation)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 27576370

Group type: EXPERIMENTAL
Intervention: Deferasirox (10 mg/kg/day starting dose, increased to 15 and 20 mg/kg/day in some patients)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Phlebotomy (6 ml/kg/2 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Deferasirox (for patients with baseline serum ferritin 1,000 ng/ml or higher)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Phlebotomy (for patients with baseline serum ferritin 1,000 ng/ml or higher)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Deferasirox and Phlebotomy (in patients with severe cardiac siderosis)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 26

Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 26
Study: 26598476

Group type: EXPERIMENTAL
Intervention: Risperidone (switched from initial medication)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Lithium (switched from initial medication)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Divalproex (switched from initial medication)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Risperidone (add-on for partial responders)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Divalproex (add-on for partial responders)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Lithium (add-on for partial responders)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Weight gain (kg) for lithium add-on
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Weight gain (kg) for risperidone add-on
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Weight gain (kg) for divalproex add-on
Number of subjects: 379

Group type: COMPARATOR
Intervention: Average weight gain comparison
Number of subjects: 379
Study: 23391764

Group type: EXPERIMENTAL
Intervention: DP-b99
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 22152181

Group type: EXPERIMENTAL
Intervention: Weekly oral tablet
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Once every 6 months subcutaneous injection
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 1583
Study: 19201093

Group type: EXPERIMENTAL
Intervention: pain re‐training
Number of subjects: 104

Group type: COMPARATOR
Intervention: neutral re‐training
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: threat induction
Number of subjects: 104

Group type: COMPARATOR
Intervention: threat alleviation
Number of subjects: 104
Study: 17989371

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 17
Study: 15582920

Group type: EXPERIMENTAL
Intervention: Methylphenidate (16, 32 and 48 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (8, 16 and 24 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11465622

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fiberoptic Intubation (FIB)
Number of subjects: 100
Study: 9494477

Group type: EXPERIMENTAL
Intervention: Subjective evaluation of motion graded on a five-point scale by two radiologists
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Objective measurements of motion determined by computer reconstruction of the rod in three dimensions
Number of subjects: 109
Study: 8306751

Group type: EXPERIMENTAL
Intervention: ICI 204,219 (0.2 mg dose)
Number of subjects: 16
Study: 3377930

Group type: EXPERIMENTAL
Intervention: 150 mg meptazinol suppository
Number of subjects: 15

Group type: COMPARATOR
Intervention: 10 mg morphine i.m.
Number of subjects: 15
Study: 31765004

Group type: EXPERIMENTAL
Intervention: Pharmacist-led education-based intervention to deprescribe inappropriate medications (sedative-hypnotics, first-generation antihistamines, selective nonsteroidal anti-inflammatory drugs, glyburide)
Number of subjects: 19144

Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (100 mg) for primary prevention
Number of subjects: 19144

Group type: COMPARATOR
Intervention: Anticholinergic exposure
Number of subjects: 19144

Group type: COMPARATOR
Intervention: Antihypertensive medications
Number of subjects: 19144
Study: 30020342

Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 15
Study: 26929616

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Befriending (active social control)
Number of subjects: 0
Study: 25163649

Group type: EXPERIMENTAL
Intervention: Virgin coconut oil (VCO) supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no VCO supplementation)
Number of subjects: 60
Study: 22520519

Group type: EXPERIMENTAL
Intervention: e-Health encouragements (SMS, Internet, and mobile applications) delivered once a week for 1 year
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 216
Study: 19015230

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 13558

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 13558

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 13558

Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 13558

Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 13558
Study: 17673816

Group type: EXPERIMENTAL
Intervention: CEOP-14 + Rituximab (CEOP-R)
Number of subjects: 196

Group type: COMPARATOR
Intervention: CEOP-14
Number of subjects: 196
Study: 15068420

Group type: EXPERIMENTAL
Intervention: Type II H. pylori
Number of subjects: 45
Study: 12537652

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 101

Group type: COMPARATOR
Intervention: Physician education
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Counseled patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tested patients
Number of subjects: 101
Study: 9825123

Group type: EXPERIMENTAL
Intervention: Phytopharmaceutical
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8209992

Group type: EXPERIMENTAL
Intervention: Bilateral infra‐orbital local anaesthetic nerve blocks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bilateral 'sham' blocks
Number of subjects: 20
Study: 2658609

Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Cefotaxime (1 gm)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 260

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Cefamandole and Cefotaxime
Number of subjects: 260
Study: 30640138

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) 25,000 IU per day for six months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 28431432

Group type: EXPERIMENTAL
Intervention: 12 mg total macular carotenoids
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 24 mg total macular carotenoids
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 25510442

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22706694

Group type: COMPARATOR
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0